1. Home
  2. UPC vs ACON Comparison

UPC vs ACON Comparison

Compare UPC & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UPC
  • ACON
  • Stock Information
  • Founded
  • UPC 1998
  • ACON 2008
  • Country
  • UPC China
  • ACON United States
  • Employees
  • UPC N/A
  • ACON N/A
  • Industry
  • UPC Biotechnology: Pharmaceutical Preparations
  • ACON Retail: Computer Software & Peripheral Equipment
  • Sector
  • UPC Health Care
  • ACON Technology
  • Exchange
  • UPC Nasdaq
  • ACON Nasdaq
  • Market Cap
  • UPC N/A
  • ACON 7.1M
  • IPO Year
  • UPC 2021
  • ACON 2022
  • Fundamental
  • Price
  • UPC $3.04
  • ACON $11.00
  • Analyst Decision
  • UPC
  • ACON Buy
  • Analyst Count
  • UPC 0
  • ACON 2
  • Target Price
  • UPC N/A
  • ACON $481.00
  • AVG Volume (30 Days)
  • UPC 803.8K
  • ACON 374.2K
  • Earning Date
  • UPC 01-01-0001
  • ACON 05-14-2025
  • Dividend Yield
  • UPC N/A
  • ACON N/A
  • EPS Growth
  • UPC N/A
  • ACON N/A
  • EPS
  • UPC N/A
  • ACON N/A
  • Revenue
  • UPC $26,725,919.00
  • ACON $49,289.00
  • Revenue This Year
  • UPC N/A
  • ACON N/A
  • Revenue Next Year
  • UPC N/A
  • ACON $186.36
  • P/E Ratio
  • UPC N/A
  • ACON N/A
  • Revenue Growth
  • UPC N/A
  • ACON N/A
  • 52 Week Low
  • UPC $0.12
  • ACON $9.75
  • 52 Week High
  • UPC $4.32
  • ACON $6,241.05
  • Technical
  • Relative Strength Index (RSI)
  • UPC 32.16
  • ACON 33.43
  • Support Level
  • UPC $3.20
  • ACON $9.75
  • Resistance Level
  • UPC $5.57
  • ACON $15.08
  • Average True Range (ATR)
  • UPC 0.77
  • ACON 3.19
  • MACD
  • UPC 0.41
  • ACON 12.72
  • Stochastic Oscillator
  • UPC 10.99
  • ACON 5.96

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Share on Social Networks: